Dyadic International (DYAI) Competitors

$0.77 +0.02 (+2.80%)

As of 04:00 PM Eastern

DYAI vs. CRDF, VRCA, IFRX, ASRT, and VTVT

Should you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Cardiff Oncology (CRDF), Verrica Pharmaceuticals (VRCA), InflaRx (IFRX), Assertio (ASRT), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry.

How does Dyadic International compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

: Cardiff Oncology has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Dyadic International has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.
: Dyadic International has higher revenue and earnings than Cardiff Oncology. Dyadic International is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cardiff Oncology $593K 184.47 -$45.85M -$0.69 N/A
Dyadic International $3.09M 9.14 -$7.36M -$0.25 N/A
: In the previous week, Dyadic International had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 1 mentions for Dyadic International and 0 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score.
Company Overall Sentiment
Cardiff Oncology Neutral
Dyadic International Neutral
: Dyadic International has a net margin of -239.67% compared to Cardiff Oncology's net margin of -7,733.22%. Cardiff Oncology's return on equity of -82.01% beat Dyadic International's return on equity.
Company Net Margins Return on Equity Return on Assets
Cardiff Oncology -7,733.22% -82.01% -64.09%
Dyadic International -239.67% -695.96% -78.24%
: 16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 7.7% of Cardiff Oncology shares are held by company insiders. Comparatively, 29.5% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Cardiff Oncology presently has a consensus target price of $10.10, indicating a potential upside of 531.25%. Dyadic International has a consensus target price of $3.00, indicating a potential upside of 287.05%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Cardiff Oncology is more favorable than Dyadic International.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
1 Sell rating(s)
1 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.57
Dyadic International
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$593K	184.47	-$45.85M	-$0.69	N/A
Dyadic International	$3.09M	9.14	-$7.36M	-$0.25	N/A

Company	Overall Sentiment
Cardiff Oncology	Neutral
Dyadic International	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,733.22%	-82.01%	-64.09%
Dyadic International	-239.67%	-695.96%	-78.24%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Cardiff Oncology beats Dyadic International on 8 of the 15 factors compared between the two stocks.

How does Dyadic International compare to Verrica Pharmaceuticals?

Dyadic International (NASDAQ:DYAI) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

: In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Dyadic International. MarketBeat recorded 4 mentions for Verrica Pharmaceuticals and 1 mentions for Dyadic International. Verrica Pharmaceuticals' average media sentiment score of 1.95 beat Dyadic International's score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyadic International
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Verrica Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
: Dyadic International has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.
: Verrica Pharmaceuticals has a net margin of -50.27% compared to Dyadic International's net margin of -239.67%. Verrica Pharmaceuticals' return on equity of 0.00% beat Dyadic International's return on equity.
Company Net Margins Return on Equity Return on Assets
Dyadic International -239.67% -695.96% -78.24%
Verrica Pharmaceuticals -50.27% N/A -40.08%
: Dyadic International currently has a consensus target price of $3.00, suggesting a potential upside of 287.05%. Verrica Pharmaceuticals has a consensus target price of $17.00, suggesting a potential upside of 137.43%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Verrica Pharmaceuticals.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyadic International
1 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
Verrica Pharmaceuticals
2 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
1.75
: 28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 29.5% of Dyadic International shares are owned by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Dyadic International has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dyadic International $3.09M 9.14 -$7.36M -$0.25 N/A
Verrica Pharmaceuticals $35.58M 3.46 -$17.89M -$1.58 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-239.67%	-695.96%	-78.24%
Verrica Pharmaceuticals	-50.27%	N/A	-40.08%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Verrica Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	9.14	-$7.36M	-$0.25	N/A
Verrica Pharmaceuticals	$35.58M	3.46	-$17.89M	-$1.58	N/A

Summary

Verrica Pharmaceuticals beats Dyadic International on 9 of the 16 factors compared between the two stocks.

How does Dyadic International compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

: InflaRx currently has a consensus price target of $5.80, suggesting a potential upside of 194.42%. Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 287.05%. Given Dyadic International's higher probable upside, analysts clearly believe Dyadic International is more favorable than InflaRx.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InflaRx
1 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
Dyadic International
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: InflaRx has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500. Comparatively, Dyadic International has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.
: 42.4% of InflaRx shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 29.5% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: In the previous week, InflaRx had 7 more articles in the media than Dyadic International. MarketBeat recorded 8 mentions for InflaRx and 1 mentions for Dyadic International. InflaRx's average media sentiment score of 0.56 beat Dyadic International's score of 0.00 indicating that InflaRx is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
InflaRx
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Dyadic International
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: InflaRx has a net margin of 0.00% compared to Dyadic International's net margin of -239.67%. InflaRx's return on equity of -80.51% beat Dyadic International's return on equity.
Company Net Margins Return on Equity Return on Assets
InflaRx N/A -80.51% -61.36%
Dyadic International -239.67% -695.96% -78.24%
: Dyadic International has higher revenue and earnings than InflaRx. Dyadic International is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InflaRx $29.33K 4,855.52 -$51.63M -$0.76 N/A
Dyadic International $3.09M 9.14 -$7.36M -$0.25 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-80.51%	-61.36%
Dyadic International	-239.67%	-695.96%	-78.24%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$29.33K	4,855.52	-$51.63M	-$0.76	N/A
Dyadic International	$3.09M	9.14	-$7.36M	-$0.25	N/A

Summary

InflaRx beats Dyadic International on 11 of the 16 factors compared between the two stocks.

How does Dyadic International compare to Assertio?

Assertio (NASDAQ:ASRT) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

: Assertio currently has a consensus price target of $19.90, suggesting a potential downside of 10.20%. Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 287.05%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts clearly believe Dyadic International is more favorable than Assertio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Assertio
1 Sell rating(s)
4 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Dyadic International
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: Assertio has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.
: 49.0% of Assertio shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 5.7% of Assertio shares are owned by company insiders. Comparatively, 29.5% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: In the previous week, Assertio had 7 more articles in the media than Dyadic International. MarketBeat recorded 8 mentions for Assertio and 1 mentions for Dyadic International. Assertio's average media sentiment score of 0.65 beat Dyadic International's score of 0.00 indicating that Assertio is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Assertio
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Dyadic International
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Assertio has a net margin of -25.59% compared to Dyadic International's net margin of -239.67%. Assertio's return on equity of -30.26% beat Dyadic International's return on equity.
Company Net Margins Return on Equity Return on Assets
Assertio -25.59% -30.26% -10.59%
Dyadic International -239.67% -695.96% -78.24%
: Dyadic International has lower revenue, but higher earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Assertio $118.71M 1.20 -$30.38M -$4.86 N/A
Dyadic International $3.09M 9.14 -$7.36M -$0.25 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-25.59%	-30.26%	-10.59%
Dyadic International	-239.67%	-695.96%	-78.24%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.20	-$30.38M	-$4.86	N/A
Dyadic International	$3.09M	9.14	-$7.36M	-$0.25	N/A

Summary

Dyadic International beats Assertio on 9 of the 16 factors compared between the two stocks.

How does Dyadic International compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

: vTv Therapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.
: vTv Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -239.67%. vTv Therapeutics' return on equity of -73.76% beat Dyadic International's return on equity.
Company Net Margins Return on Equity Return on Assets
vTv Therapeutics N/A -73.76% -43.53%
Dyadic International -239.67% -695.96% -78.24%
: 17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 4.2% of vTv Therapeutics shares are held by company insiders. Comparatively, 29.5% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Dyadic International has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
vTv Therapeutics N/A N/A -$26.97M -$3.35 N/A
Dyadic International $3.09M 9.14 -$7.36M -$0.25 N/A
: vTv Therapeutics presently has a consensus price target of $53.00, suggesting a potential upside of 66.67%. Dyadic International has a consensus price target of $3.00, suggesting a potential upside of 287.05%. Given Dyadic International's higher probable upside, analysts clearly believe Dyadic International is more favorable than vTv Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
vTv Therapeutics
1 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
Dyadic International
1 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
: In the previous week, Dyadic International had 1 more articles in the media than vTv Therapeutics. MarketBeat recorded 1 mentions for Dyadic International and 0 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 1.95 beat Dyadic International's score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
vTv Therapeutics Very Positive
Dyadic International Neutral

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-73.76%	-43.53%
Dyadic International	-239.67%	-695.96%	-78.24%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	N/A	N/A	-$26.97M	-$3.35	N/A
Dyadic International	$3.09M	9.14	-$7.36M	-$0.25	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Company	Overall Sentiment
vTv Therapeutics	Very Positive
Dyadic International	Neutral

Summary

Dyadic International beats vTv Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Dyadic International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYAI vs. The Competition

Export

Metric	Dyadic International	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.25M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-3.10	38.85	29.04	28.47
Price / Sales	9.14	155.51	476.61	60.92
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	25.84	7.03	9.67	6.67
Net Income	-$7.36M	$23.62M	$3.55B	$332.53M
7 Day Performance	-4.32%	3.68%	1.70%	2.01%
1 Month Performance	-12.91%	7.16%	5.62%	9.19%
1 Year Performance	-34.31%	67.05%	34.41%	39.59%

Dyadic International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYAI Dyadic International	2.1191 of 5 stars	$0.78 +3.2%	$3.00 +287.0%	N/A	$28.25M	$3.09M	N/A	7
CRDF Cardiff Oncology	0.9242 of 5 stars	$1.68 -2.3%	$10.10 +501.2%	N/A	$117.60M	$590K	N/A	20
VRCA Verrica Pharmaceuticals	2.0072 of 5 stars	$6.53 -4.3%	$17.00 +160.3%	N/A	$117.25M	$35.58M	N/A	40	News Coverage Positive News Upcoming Earnings
IFRX InflaRx	3.6036 of 5 stars	$1.67 +3.7%	$5.80 +247.3%	N/A	$116.39M	$30K	N/A	60	News Coverage Upcoming Earnings High Trading Volume
ASRT Assertio	2.3063 of 5 stars	$18.04 flat	$18.00 -0.2%	N/A	$116.27M	$118.71M	N/A	20	News Coverage Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYAI) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyadic International (DYAI) Competitors

DYAI vs. CRDF, VRCA, IFRX, ASRT, and VTVT

How does Dyadic International compare to Cardiff Oncology?

Summary

How does Dyadic International compare to Verrica Pharmaceuticals?

Summary

How does Dyadic International compare to InflaRx?

Summary

How does Dyadic International compare to Assertio?

Summary

How does Dyadic International compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyadic International (DYAI) Competitors

DYAI vs. CRDF, VRCA, IFRX, ASRT, and VTVT

How does Dyadic International compare to Cardiff Oncology?

Summary

How does Dyadic International compare to Verrica Pharmaceuticals?

Summary

How does Dyadic International compare to InflaRx?

Summary

How does Dyadic International compare to Assertio?

Summary

How does Dyadic International compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools